Velcade®, Melphalan, and Prednisone Improves Survival of Patients with Multiple Myeloma Not Eligible for Transplant(9/3/2008) Researchers affiliated with the VISTA international study have reported that VMP (Velcade® [bortezomib], melphalan, and prednisone) improves survival of patients with multiple myeloma who are not candidates for stem cell transplantation compared with the classic MP (melphalan and prednisone) regimen. The details of this randomized study were presented at the 2007 meeting of the American Society of Hematology in December in Atlanta, Georgia, and have now been published in the August 28, 2008 issue of the New England Journal of Medicine.
Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?(6/19/2008) Researchers from the University of Arkansas have reported a 10% continuous complete remission rate for patients with newly diagnosed multiple myeloma (MM) who are treated with chemotherapy induction, tandem autotransplants, and interferon maintenance. These researchers also suggest that continued improvements in a “total therapy” (TT) approach should increase this 10% “cure” rate. The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2.
Velcade® (Bortezomib) Adds to Effectiveness of Thalomid® (Thalidomide) and Dexamethasone for Myeloma(1/14/2008) Researchers affiliated with the Italian Myeloma Network have reported that a regimen of Velcade (bortezomib), Thalomid (thalidomide) and dexamethasone (VDT) results in a higher complete response rate than Thalomid and dexamethasone (TD) for the initial treatment of patients with multiple myeloma. The details of this randomized trial were presented at the 2007 meeting of the American Society of Hematology in December in Atlanta, Georgia.
Melphalan, Prednisone and Revlimid for Induction Theapy of Multiple Myeloma(10/12/2007) Researchers from Italy have reported that a regime of melphalan, prednisone and Revlimid (lenalidomide) produces a partial response or greater in 81% of newly diagnosed patients with multiple myeloma. The details of this study appeared in the October 1, 2007 issue of the Journal of Clinical Oncology.
Velcade®, Melphalan, and Prednisone Improves Survival of Patients with Multiple Myeloma Not Eligible for Transplant(9/3/2008) Researchers affiliated with the VISTA international study have reported that VMP (Velcade® [bortezomib], melphalan, and prednisone) improves survival of patients with multiple myeloma who are not candidates for stem cell transplantation compared with the classic MP (melphalan and prednisone) regimen. The details of this randomized study were presented at the 2007 meeting of the American Society of Hematology in December in Atlanta, Georgia, and have now been published in the August 28, 2008 issue of the New England Journal of Medicine.
Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?(6/19/2008) Researchers from the University of Arkansas have reported a 10% continuous complete remission rate for patients with newly diagnosed multiple myeloma (MM) who are treated with chemotherapy induction, tandem autotransplants, and interferon maintenance. These researchers also suggest that continued improvements in a “total therapy” (TT) approach should increase this 10% “cure” rate. The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2.
Velcade® (Bortezomib), Melphalan and Dexamethasone Improves Survival of Patients with Multiple Myeloma Who are not Transplant Candidates(1/16/2008) Researchers affiliated with the VISTA international study have reported that VMP (Velcade® (bortezomib), melphalan and prednisone) improves survival of patients with multiple myeloma who are not candidates for stem cell transplantation compared to the classic MP (melphalan and prednisone) regimen. The details of this randomized study were presented at the 2007 meeting of the American Society of Hematology in December in Atlanta, Georgia.
High-Dose Dexamethasone Increases Mortality Compared to Low-Dose Dexamethasone When Combined with Revlimid® (Lenolidomide) for Multiple Myeloma(1/18/2008) Researchers affiliated with the Eastern Cooperative Group (Study E4A03) have reported that Revlimid® (lenalidomide) plus high-dose dexamethasone (dex) is associated with a higher death rate than seen following Revlimid and low-dose dex for initial treatment of patients with multiple myeloma. The details of this randomized trial were presented at the 2007 meeting of the American Society of Hematology in December in Atlanta, Georgia.
Revlimid® Plus Dexamethasone Improves Survival in Relapsed Multiple Myeloma(11/26/2007) Two randomized controlled trials have reported that Revlimid (linalidomide) plus dexamethasone is superior to dexamethasone alone for the treatment of relapsed multiple myeloma. The details of these studies appeared in the November 22, 2007 issue of The New England Journal of Medicine.
Velcade® Indication Expanded to Include Patients with Impaired Kidney Function(10/17/2007) Millennium Pharmaceuticals, Inc. has received an expanded indication for their agent Velcade (bortezomib) from the United States Food and Drug Administration (FDA) to include patients with multiple myeloma who have impaired kidney function, including those who require dialysis.
Double Autografts Improve Progression-Free Survival in Patients with Myeloma(6/26/2007) Researchers from Italy have reported that newly diagnosed patients with multiple myeloma have improved responses and relapse-free and event-free survivals following double autologous transplants compared to a single autologous transplant but there was no improvement in overall survival. The details of this study were published in the June 10, 2007 issue of the Journal of Clinical Oncology.
Patient Home
